Oct 23, 2012 by Brian Orelli, PhD3 Diabetes Phase 3 WinsLilly's diabetes drug dulaglutide tops the competition in three phase 3 trials.
Oct 22, 2012 by Brian Orelli, PhDFDA Lightens Up on Obesity DrugsOrexigen says the FDA will review Contrave as quickly as possible.
Oct 19, 2012 by Brian Orelli, PhD1 Stem-Cell Spinout You Must WatchBioTime's proposal for Geron's stem cell program will benefit shareholders more than the company.
Oct 18, 2012 by Brian Orelli, PhDVIVUS Seeks to Expand Market ReachVIVUS asks the FDA to allow sales of Qsymia at retail pharmacies.
Oct 17, 2012 by Brian Orelli, PhDAn FDA Decision Is on the MAPMAP Pharma resubmits Levadex for FDA approval.
Oct 16, 2012 by Brian Orelli, PhDA Puny Drug Deal for Blockbuster IndicationsTheravance licenses its preclinical cardiovascular program to Merck.
Oct 15, 2012 by Brian Orelli, PhD3 Things to Watch at Ariad PharmaceuticalsThe pipeline is just as important as its lead compound ponatinib.
Oct 15, 2012 by Brian Orelli, PhDA Hep C Hip CheckAbbott presents solid data for its hepatitis C drug combination.
Oct 15, 2012 by Brian Orelli, PhDConfounding Combo DataVertex's cystic fibrosis data isn't as clean as investors would hope.
Oct 15, 2012 by Brian Orelli, PhDThe Pain of Developing Pain DrugsHigh dropout rates and the pacebo effect aren't fun.
Oct 15, 2012 by Brian Orelli, PhDSide Effects? What Side Effects?FDA briefing documents brush off side-effect issues for NPS Pharma's Gattex.
Oct 11, 2012 by Brian Orelli, PhD3 Biotechs Facing the Firing Squad Next WeekNPS Pharma, Aegerion, and Isis face FDA advisory committee meetings.
Oct 10, 2012 by Brian Orelli, PhDBackup Plan Delayed. Again.The FDA continues to delay making a decision about the NCE status of Amarin's Vascepa.
Oct 9, 2012 by Brian Orelli, PhDMore Patients! But, Will They Pay?VIVUS signs up Express Scripts to sell its obesity drug Qsymia.
Oct 9, 2012 by Brian Orelli, PhDStock's Up 20% on Hope From a Failed TrialEli Lilly's investors need to be careful reading into this.
Oct 8, 2012 by Brian Orelli, PhDCan a Reverse Split Reverse the Trend?Aeterna Zentaris increases its share price by reverse splitting.
Oct 5, 2012 by Brian Orelli, PhDExtending the Diabetes DominanceMerck's once-weekly diabetes drug, MK-3102, produces good phase 2 data.
Oct 4, 2012 by Brian Orelli, PhDThis Big Pharma Pair Parts WaysAfter generics hit the market, long-time partners Bristol and Sanofi, call it mostly quits.
